Lineage Cell Therapeutics...

0.47
-0.02 (-4.45%)
At close: Mar 31, 2025, 12:57 PM
-4.45%
Bid 0.47
Market Cap 103.49M
Revenue (ttm) 10.84M
Net Income (ttm) -21.23M
EPS (ttm) -0.09
PE Ratio (ttm) -5.22
Forward PE -6.3
Analyst Buy
Ask 0.47
Volume 749,398
Avg. Volume (20D) 1,803,815
Open 0.49
Previous Close 0.49
Day's Range 0.45 - 0.48
52-Week Range 0.46 - 1.56
Beta 1.28

About LCTX

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa mul...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 5, 1992
Employees 70
Stock Exchange AMEX
Ticker Symbol LCTX
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for LCTX stock is "Buy." The 12-month stock price forecast is $3, which is an increase of 538.98% from the latest price.

Stock Forecasts

Next Earnings Release

Lineage Cell Therapeutics Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-28.99%
Lineage Cell Therapeutics shares are trading lower... Unlock content with Pro Subscription
7 months ago
+1.8%
Lineage Cell Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results.